MAP Pharmaceuticals

Allergan PLC has seized on an opportunity to reach the market with oral calcitonin gene-related peptide (CGRP) receptor antagonists for the treatment and prevention of migraine through a licensing d

Sanofi has paid $45m via an upfront licensing fee and equity investment in young South San Francisco-based biotech MyoKardia, which is developing targeted therapies for genetic heart disease. The coll

Allergan Inc. received a third “complete response” letter for Semprana (dihydroergotamine) for the treatment of acute migraine, the company announced June 30, raising questions about the near-term

For the third time, the FDA has rejected Allergan's experimental inhaled migraine drug dihydroergotamine, which has now changed its moniker from Levadex to Semprana. But the agency also approved the c